Literature DB >> 25623121

Obesity. A new paradigm for treating obesity and diabetes mellitus.

André J Scheen1, Nicolas Paquot1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 25623121     DOI： 10.1038/nrendo.2015.3

Source DB:  PubMed          Journal:  Nat Rev Endocrinol        ISSN： 1759-5029            Impact factor:   43.330


× No keyword cloud information.
  10 in total

Review 1.  Glucagonocentric restructuring of diabetes: a pathophysiologic and therapeutic makeover.

Authors:  Roger H Unger; Alan D Cherrington
Journal:  J Clin Invest       Date:  2012-01-03       Impact factor: 14.808

2.  Glucagon regulates orexin A secretion in humans and rodents.

Authors:  Ayman M Arafat; Przemysław Kaczmarek; Marek Skrzypski; Ewa Pruszyńska-Oszmałek; Paweł Kołodziejski; Aikaterini Adamidou; Stephan Ruhla; Dawid Szczepankiewicz; Maciej Sassek; Maria Billert; Bertram Wiedenmann; Andreas F H Pfeiffer; Krzysztof W Nowak; Mathias Z Strowski
Journal:  Diabetologia       Date:  2014-07-27       Impact factor: 10.122

Review 3.  Incretin-based therapies.

Authors:  Joshua J Neumiller
Journal:  Med Clin North Am       Date:  2014-10-18       Impact factor: 5.456

Review 4.  Emerging combinatorial hormone therapies for the treatment of obesity and T2DM.

Authors:  Sharon A Sadry; Daniel J Drucker
Journal:  Nat Rev Endocrinol       Date:  2013-03-12       Impact factor: 43.330

Review 5.  Pharmacology, physiology, and mechanisms of incretin hormone action.

Authors:  Jonathan E Campbell; Daniel J Drucker
Journal:  Cell Metab       Date:  2013-05-16       Impact factor: 27.287

Review 6.  Glucagon and type 2 diabetes: the return of the alpha cell.

Authors:  Asger Lund; Jonatan I Bagger; Mikkel Christensen; Filip K Knop; Tina Vilsbøll
Journal:  Curr Diab Rep       Date:  2014-12       Impact factor: 4.810

7.  A rationally designed monomeric peptide triagonist corrects obesity and diabetes in rodents.

Authors:  Brian Finan; Bin Yang; Nickki Ottaway; David L Smiley; Tao Ma; Christoffer Clemmensen; Joe Chabenne; Lianshan Zhang; Kirk M Habegger; Katrin Fischer; Jonathan E Campbell; Darleen Sandoval; Randy J Seeley; Konrad Bleicher; Sabine Uhles; William Riboulet; Jürgen Funk; Cornelia Hertel; Sara Belli; Elena Sebokova; Karin Conde-Knape; Anish Konkar; Daniel J Drucker; Vasily Gelfanov; Paul T Pfluger; Timo D Müller; Diego Perez-Tilve; Richard D DiMarchi; Matthias H Tschöp
Journal:  Nat Med       Date:  2014-12-08       Impact factor: 53.440

Review 8.  Combating the dual burden: therapeutic targeting of common pathways in obesity and type 2 diabetes.

Authors:  André J Scheen; Luc F Van Gaal
Journal:  Lancet Diabetes Endocrinol       Date:  2014-02-19       Impact factor: 32.069

9.  Coinfusion of low-dose GLP-1 and glucagon in man results in a reduction in food intake.

Authors:  Jaimini Cegla; Rachel C Troke; Ben Jones; George Tharakan; Julia Kenkre; Katherine A McCullough; Chung Thong Lim; Nassim Parvizi; Mohamed Hussein; Edward S Chambers; James Minnion; Joyceline Cuenco; Mohammad A Ghatei; Karim Meeran; Tricia M Tan; Stephen R Bloom
Journal:  Diabetes       Date:  2014-06-17       Impact factor: 9.461

10.  Coadministration of glucagon-like peptide-1 during glucagon infusion in humans results in increased energy expenditure and amelioration of hyperglycemia.

Authors:  Tricia M Tan; Benjamin C T Field; Katherine A McCullough; Rachel C Troke; Edward S Chambers; Victoria Salem; Juan Gonzalez Maffe; Kevin C R Baynes; Akila De Silva; Alexander Viardot; Ali Alsafi; Gary S Frost; Mohammad A Ghatei; Stephen R Bloom
Journal:  Diabetes       Date:  2012-12-17       Impact factor: 9.461
  10 in total
  2 in total

Review 1.  Trends in the Diabetes Epidemic in Korea.

Authors:  Kyoung Hwa Ha; Dae Jung Kim
Journal:  Endocrinol Metab (Seoul)       Date:  2015-05-18

2.  An online tool for obesity intervention and public health.

Authors:  Jason G Su
Journal:  BMC Public Health       Date:  2016-02-10       Impact factor: 3.295
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.